CN108938864A - A kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases - Google Patents
A kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases Download PDFInfo
- Publication number
- CN108938864A CN108938864A CN201810630565.6A CN201810630565A CN108938864A CN 108938864 A CN108938864 A CN 108938864A CN 201810630565 A CN201810630565 A CN 201810630565A CN 108938864 A CN108938864 A CN 108938864A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- weight
- drug
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 229940079593 drug Drugs 0.000 title claims abstract description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 30
- 201000010099 disease Diseases 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 208000029433 Herpesviridae infectious disease Diseases 0.000 title claims abstract description 17
- 208000007514 Herpes zoster Diseases 0.000 claims abstract description 37
- 208000002352 blister Diseases 0.000 claims abstract description 15
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 13
- 244000080767 Areca catechu Species 0.000 claims abstract description 13
- 235000006226 Areca catechu Nutrition 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 13
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 13
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 13
- 241001522129 Pinellia Species 0.000 claims abstract description 13
- 244000197580 Poria cocos Species 0.000 claims abstract description 13
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 13
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 13
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims abstract description 13
- 239000001738 pogostemon cablin oil Substances 0.000 claims abstract description 13
- 208000004296 neuralgia Diseases 0.000 claims abstract description 12
- 239000000706 filtrate Substances 0.000 claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 22
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 19
- 208000002193 Pain Diseases 0.000 claims description 18
- 230000036407 pain Effects 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 17
- 235000019441 ethanol Nutrition 0.000 claims description 11
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 8
- 210000002216 heart Anatomy 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- 238000009738 saturating Methods 0.000 claims description 6
- 208000009889 Herpes Simplex Diseases 0.000 claims description 5
- 241000175212 Herpesvirales Species 0.000 claims description 4
- 206010040882 skin lesion Diseases 0.000 claims description 3
- 231100000444 skin lesion Toxicity 0.000 claims description 3
- 241000700584 Simplexvirus Species 0.000 claims description 2
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 229960004150 aciclovir Drugs 0.000 abstract description 7
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000004630 mental health Effects 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000007910 systemic administration Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 239000000470 constituent Substances 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 244000273928 Zingiber officinale Species 0.000 description 5
- 235000006886 Zingiber officinale Nutrition 0.000 description 5
- 235000008397 ginger Nutrition 0.000 description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- -1 filtration Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000004898 Herpes Labialis Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010067152 Oral herpes Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229940035613 prozac Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- LJRIQCOECCOZGF-YNHQPCIGSA-N (4R,4aR,7aR,12bS)-9-hydroperoxy-3-methyl-1,2,4,4a,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one Chemical compound OOC=1C=CC=2C[C@@H]3[C@@H]4C=CC([C@H]5[C@@]4(C=2C=1O5)CCN3C)=O LJRIQCOECCOZGF-YNHQPCIGSA-N 0.000 description 1
- 101800000535 3C-like proteinase Proteins 0.000 description 1
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 206010005372 Blood blister Diseases 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 241001013934 Erigeron breviscapus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 208000003809 Herpes Zoster Ophthalmicus Diseases 0.000 description 1
- LHFKHAVGGJJQFF-UEOYEZOQSA-N Hydroxy-alpha-sanshool Chemical compound C\C=C\C=C\C=C/CC\C=C\C(=O)NCC(C)(C)O LHFKHAVGGJJQFF-UEOYEZOQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010030865 Ophthalmic herpes zoster Diseases 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 210000003192 autonomic ganglia Anatomy 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- XXPVSQRPGBUFKM-SAPNQHFASA-N clovoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(Cl)C=C1 XXPVSQRPGBUFKM-SAPNQHFASA-N 0.000 description 1
- 229950002663 clovoxamine Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940125676 combination antiviral drug Drugs 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- BRTSNYPDACNMIP-FAWZKKEFSA-N dihydroetorphine Chemical compound O([C@H]1[C@@]2(OC)CC[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O BRTSNYPDACNMIP-FAWZKKEFSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- 229940105606 oxycontin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases, the Traditional Chinese medicine composition formula is as follows: 80 parts by weight of rhizoma atractylodis, 80 parts by weight of dried orange peel, 80 parts by weight of Cortex Magnoliae Officinalis, 120 parts by weight of the root of Dahurain angelica, 120 parts by weight of Poria cocos, 120 parts by weight of the shell of areca nut, 80 parts by weight of dried pinellia, 0.4 parts by volume of 10 parts by weight of extract of licorice root, 0.8 parts by volume of patchouli oil and perilla leaf oil.Chinese medicine composition of the invention uses traditional Chinese medicine for raw material, and toxic side effect is small, and treatment shingles zoster effect is obvious, and can prevent and treat postherpes neuralgia PHN.Either systemic administration or local application, effect are better than bleb common medicine acyclovir.Chinese medicine composition of the invention can shorten bleb cure time, and patient is allowed to walk out disease shade as early as possible, beneficial to the physical and mental health of patient.
Description
The invention belongs to field of medicaments, and in particular to a kind of Chinese medicine composition is in preparation treatment herpesviral associated diseases
Application in drug.
Background technique
Virus infected herpes (HerpesSimplex) are one kind by the virogenetic virus dermatopathy of virus infected herpes.Point
Herpes simplex and shingles zoster, wherein shingles zoster be by varicellazoster virus (varicella zoster virus,
VZV a kind of skin disease of acute herpetic caused by).VZV is a kind of common mankind a herpesviral, and form is in brick, outside
There is capsid coating in portion, and diameter is about 150-200nm, inside there is double-stranded DNA.VZV is there are two types of main protease: archaeal dna polymerase and
Thymidine kinase.Archaeal dna polymerase is that DNA synthesis institute is required, and the latter may be related with hiding for virus.Virus has very strong
Neural invasion, and people is its unique natural reservoir (of bird flu viruses).It can cause varicella in primary infection, this when, VZV was in different devices
It is bred in official, especially skin.After varicella recovery from illness, VZV can hide the neuromere of root, autonomic ganglia after spinal nerve
Equal positions.When lower for the resistance, tired, infection or flu, virus can be activated again, assemble new virus from nerve
In section, corresponding skin epidermis is reached along the nerve fibre of surrounding, causes the vesicle of segmental.It is propagated in spite of apparent
There is the report of viremia virusemia in path in the VZV activation of limitation, in skin bleb and the relevant pain of bleb,
The blister for being mainly characterized by having gathering shape of viral DNA shingles zoster in detectable peripheral blood mononuclear cells, generally along body
Zonal distribution is presented in body unilateral side peripheral nerve, can increase with significant nerve pain and regional nodes, this nerve dysmenorrhea
It can be often chronic.In addition, virus can transport to other positions by nerve, cause meningitis, vascular lesion, cranial nerve fiber crops disease and
Herpes zoster ophthalmicus etc..
Epidemiology tune Check data shows, shingles zoster and post-herpetic neuralgia (postherpetic
Neuralgia, PHN) disease incidence show the trend gradually increased.Post-herpetic neuralgia is herpes digitalis clinical healing
Pain lasts one month or more afterwards, about 20% Patients with Herpes Zoster had pain in report in 3 months after the onset,
15% patient report after morbidity 2 years has pain.Some researches show that post-herpetic neuralgia is close with the age
Correlation, with advancing age, the probability of morbidity are higher, and especially 60 years old or more patient morbidity is higher.There are some researches prove bands
After shape bleb patient recovery from illness, there is 9-19% patient to have post herpetic neuralgia.Due to the duration of pain, severity and treatment is arranged
The insensitivity applied, PHN cause huge harm to the body and mental health of patient, it is not only interfered, and patient's is normal
Social activities, can also be from causing patient that insomnia, loss of appetite occurs, and serious person even can develop into depression, serious shadow
Ring the quality of life of Patients with Herpes Zoster.
PHN there is no effective etiological treatment method, and treatment is mainly to promote based on repairing of neural injury and function adjust, medicine
Object treatment is most basic and most common method." Chinese pain medicine magazine " 2016.22 (3) disclose " refreshing after shingles zoster
Dysmenorrhoea diagnosis and treatment China Consensus of experts " combines European neurology in 2010 can alliance (European Federation of
Neurological Societies, EFNS), American Psychiatry disease association (American Academy of in 2004
Neurology, AAN) recommendation to PHN drug therapy, International Society of Pain (International in 2015
Association for the Study of Pain, IASP) the special interest group of neurogenic pain (NeuPSIG) is right
The recommendation of neurogenic pain drug therapy and the clinical evidence of different pharmaceutical, the first-line drug that PHN is treated in recommendation include
Agents of calcium ion channel modulators (Pregabalin and Gabapentin), tricyclic antidepressant (amitriptyline) and 5% lidocaine patch
Agent, Second line Drug include opioid drug and C16H25NO2.But said medicine each have certain adverse reaction, especially
It is dizzy, drowsiness etc..Therefore, it is good to develop a kind of shingles zoster effect for the treatment of, Small side effects especially can be treated effectively band-like
The demand of the drug of the post herpetic neuralgia of bleb is very urgent.
Granted patent CN103079574B discloses a kind of polyethylene glycol composition, and wherein polyethylene glycol can be separately as
Active constituent uses, and can also be used with other active components such as combination antiviral drugs, although the patent claims polyethylene glycol group
Herpes labialis, genital herpes and shingles zoster can be treated by closing object, but only describe polyethylene glycol combination in the description
Object treats the pharmacological evaluation of herpes labialis, and the pharmacological activity of shingles zoster can be treated by not disclosing the composition, and this field is public
Know, herpes labialis and shingles zoster are belonging respectively to two distinct types of virus infection.
Granted patent CN100341532C discloses a kind of external preparation for treating bleb, uses kuh-seng, propolis, tree peony
Skin, erigeron breviscapus extract prepare external preparation, but the external preparation not on the books is to post-herpetic neuralgia
Therapeutic effect how.
Summary of the invention
Herpesviral associated diseases are treated in preparation in view of this, the purpose of the present invention is to provide a kind of Chinese medicine compositions
Drug in application, Chinese medicine composition of the invention can treat rapidly shingles zoster and post herpetic neuralgia, and improve other
Clinical symptoms and shingles zoster adversely affect patient body, spiritual bring, curative for effect, easy to use, have wide
Market application prospect.
The formula of Chinese medicine composition of the invention is as follows: 80 parts by weight of rhizoma atractylodis, 80 parts by weight of dried orange peel, 80 parts by weight of Cortex Magnoliae Officinalis,
120 parts by weight of the root of Dahurain angelica, 120 parts by weight of Poria cocos, 120 parts by weight of the shell of areca nut, 80 parts by weight of dried pinellia, 10 parts by weight of extract of licorice root,
0.4 parts by volume of 0.8 parts by volume of patchouli oil and perilla leaf oil.
Such as without special specified, the unit of weight of the parts by weight in the traditional chinese medicine composition of the invention formula and the volume list of parts by volume
Position is matching relationship.That is: when the unit of weight of parts by weight is Kg, the volume unit of parts by volume is L；When the weight list of parts by weight
When position is g, the volume unit of parts by volume is mL.The preferred ginger Cortex Magnoliae Officinalis of Cortex Magnoliae Officinalis mentioned by the present invention.
The preparation method of Chinese medicine composition of the invention includes the following steps: to prepare above-mentioned Chinese medicine by formula ratio, rhizoma atractylodis,
Dried orange peel, the root of Dahurain angelica, Cortex Magnoliae Officinalis add 60% ethyl alcohol to extract, filtration, and filtrate is spare；Poria cocos, the shell of areca nut add water to cook, decocting liquid filtration, filtrate
It is spare；Dried pinellia is soaked in water, and after bubble to the saturating heart, is separately added 13.5 parts by weight of rhizoma zingiberis, is added water to cook, decocting liquid filtration, and filtrate is standby
With；Extract of licorice root is smashed rear boiling and is melted, filtration, and filtrate is spare；Merge above-mentioned filtrate；It is mixed that patchouli oil, perilla leaf oil is added
It is even.
Chinese medicine composition of the invention is for can directly give in the form of a solution, can also prepare as needed when treating
Any pharmaceutically acceptable dosage form.The pharmaceutically acceptable dosage form include Chinese medicine composition of the invention and it is optional a kind of or
A variety of pharmaceutically acceptable carriers, diluent or excipient and the addition of suitable step in above-mentioned preparation process.The present invention
Used term " pharmaceutically acceptable " refers to such compound, raw material, composition and/or dosage form, they are reasonable
In the range of medical judgment, be suitable for contacted with patient tissue and without excessive toxicity, irritation, allergy or with reasonable benefit
The symmetrical other problems of benefit/Hazard ratio and complication, and effective for given application.
Pharmaceutical preparation is suitable for being administered by any suitable approach, for example, by take orally (including oral cavity or sublingual), rectum,
Nose, part (including oral cavity, sublingual or percutaneous), vagina or parenteral (including subcutaneous, intradermal, intramuscular, intra-articular, intrasynovial, chest
Bone is interior, intrathecal, intralesional, intravenous or intradermal injection or infusion) approach.It can be by any known method of art of pharmacy
This kind of preparation is prepared, such as by mixing active constituent with carrier or excipient.It is preferred that oral administration, local administration or injection
Administration.
Pharmaceutical preparation suitable for oral administration is provided by independent unit, such as the solution in aqueous or non-aqueous liquid
Or suspension；Capsule or tablet；Powder or granule；Edible foam formulations or foaming preparations etc..
For example, for oral administration in the form of a tablet or capsule, active medicine component can with can pharmaceutically connect
The oral, non-toxic inert carrier (such as ethyl alcohol, glycerol, water etc.) received mixes.By the way that compound powder is broken into suitable fine ruler
It is very little, and mix with the pharmaceutical carrier (such as the edible carbohydrate such as starch or mannitol) equally crushed to prepare powder.Also
Corrigent, preservative, dispersing agent and colorant may be present.
It by preparing pulverulent mixture as described above, and is loaded into the gelatin shell of forming, to prepare capsule.It is filling
It fills out before operation, it can be by glidant and lubricant (such as colloidal silicon dioxide, talcum powder, magnesium stearate, calcium stearate or solid-state
Polyethylene glycol) it is added in pulverulent mixture.Can also be added when taking capsule by improve drug utilizability disintegrating agent or
Solubilizer (such as agar, calcium carbonate or sodium carbonate).
When furthermore needing or is required, suitable adhesive, lubricant, disintegrating agent and colorant can also be mixed mixture
In.Suitable adhesive includes starch, gelatin, natural sugar (such as glucose or beta lactose), corn sweetener, natural and synthesis
Gummy (such as gum arabic, tragacanth or mosanom), carboxymethyl cellulose, polyethylene glycol etc..For these dosage forms
Lubricant includes enuatrol, sodium chloride etc..Disintegrating agent includes but is not limited to starch, methylcellulose, agar, bentonite, xanthan
Glue etc..For example, lubricant and disintegrating agent is added by the way that pulverulent mixture, granulation or pre- tabletting is made, and it is tabletted, to make
At tablet.By the compound suitably crushed and diluent as described above or base-material, optionally with adhesive, (such as carboxymethyl is fine
Tie up element, alginates, gelatin or polyvinylpyrrolidone), dissolve inhibitor (such as paraffin), absorbsion accelerator (quaternary salt) and/or
Absorbent (such as bentonite, kaolin or Dicalcium Phosphate) mixing, to prepare pulverulent mixture.Useful binders (such as syrup, shallow lake
Slurry, mucialga of arabic gummy or cellulosic material or polymeric material solution) wetting after pressurize sieving, pulverulent mixture is pelletized.System
One alternative of grain is can be made by pulverulent mixture by tablet press machine the result is that will form bad agglomerate and smash again
Particle.Can be by the way that stearic acid, stearate be added, talcum powder or mineral oil make particle lubrication to prevent from adhering to the punch die of tablet press machine
On.Then the mixture through lubricating is tabletted.The compound of the content of present invention can also be mixed with the inert carrier of free-flowing
It closes, it can be tabletted without passing through granulation or pre- tableting step.It can provide transparent or opaque by shellac seal coat, sugar-coat
Or the protectiveness coating material of polymeric material clothing and wax polishing clothing composition.Dyestuff can be added in these coating materials to distinguish
Different unit doses.
Oral liquid such as solution, syrup and elixir can be prepared with dosage unit form, so that specified rate contains
There is the compound of predetermined amount.Syrup can be prepared by the way that compound to be dissolved in suitably seasoned aqueous solution, and elixir can lead to
It crosses using non-toxic vehicle and prepares.Can also be added preservative, flavoring additive (such as peppermint oil or natural sweetener or saccharin or
Other artificial sweeteners) etc..
Pharmaceutical preparation suitable for percutaneous dosing can be used as discrete patch to keep close with recipient's epidermis in a long time
Cut-grafting touching.For example, active constituent can be by passing medicine by electro-ionic osmosis patch, usually reference can be made to Pharmaceutical
Research1986,3(6),318。
Pharmaceutical preparation suitable for local administration can be made into ointment, cream, suspension, lotion, powder, solution, paste
Agent, gelling agent, spray, aerosol, oil formulation or transdermal patch.
Pharmaceutical preparation (wherein carrier is solid) suitable for nose administration includes that partial size is such as 20-500 micron range
Dust base is quickly sucked from the coarse powder agent container close to nose by being administered in a manner of snuffing by nasal passage.Wherein carry
Body is liquid, is suitable for aqueous solution agent or oil that the appropriate formulation that nasal mist or nasal drop are administered includes active constituent
Property solution.
Include minuteness particle pulvis or mist agent suitable for the pharmaceutical preparation by inhalation, can be measured with different type
Dosage compresed gas aerosol, nebulizer, insufflator or other matters delivering aerosol spray device in prepare.
Pharmaceutical preparation suitable for parenteral includes water-based and non-aqueous sterile injection solution and aqueous and non-aqueous
Sterile suspensions, water-based and non-aqueous sterile injection solution can contain antioxidant, buffer, bacteriostatic agent and make the preparation
The isotonic solute with receptor's blood waiting.Preparation can be provided with unit dose or multi-dose container, such as the peace of sealing is triumphant and small
Bottle, and can be reserved under the conditions of freeze-drying (freeze-drying), only sterile liquid carrier, such as water for injection need to be added before use.
The injection solution for facing used time configuration can be prepared by sterile powder injection, granule and tablet.
Pharmaceutical preparation can be in unit dosage forms, and each unit dose contains the active constituent of predetermined amount.Dose regimen can be used as growing
Phase or short-term therapy.Mixing with carrier material will be according to disease to be treated, disease to prepare the amount of the active constituent of single formulation
Disease severity, administration time, administration route, the discharge rate of compound used therefor, treatment time and patient age, gender,
Weight and situation and change.Preferred unit dosage forms are the daily dose containing above-mentioned active constituent or divided dose or its appropriate fraction
Unit dosage forms.It can start to treat with the low dose of already clearly below compound optimal dose.Hereafter, it is increased with lesser increment
Dosage until reaching optimum efficiency in this case.In general, the concentration level for most desirably giving compound is usual
Effective result can be provided without regard to causing any harmful or toxic side effect in anti-virus aspect.
When composition of the invention can also be with the combination of one or more other treatment drugs or prophylactic agent, compound
Dosage level with other drug accounts for the about 10-150% of normal dosage, more preferably usually in monotherapy scheme
Account for the about 10-80% of normal dosage.
Preferably, Chinese medicine composition of the invention can with include but is not limited to following treatment shingles zoster activity at
Divide and be used in combination: antiviral treatment: acyclovir, Valaciclovir, famciclovir or Ganciclovir；Neuralgia drug is controlled
Treat: 1. antidepressants key agents have Paxil (Sai Lete), Prozac (prozac), Clovoxamine, Sertraline etc.；②
Anticonvulsive drug has carbamazepine, sodium vedproate etc..3. narcotic analgeiscs is using morphine as the analgesic of representative.Available medicine
Object has morphine (Morphine), hydroxymorphinone (OxyContin), Oxycodone, fentanyl (Durogesic), dihydroetorphine, Lu Gai
Gram etc..4. non-narcotic analgesics include NSAIDs, bent more, aconite alkaloid, capsaicine etc..
Herpesvirus infection mentioned by the present invention includes herpes simplex virus I-type, II type and varicellazoster virus institute
The herpes simplex viral infections and herpes zoster virus infection of cause.
Herpesvirus infection associated diseases mentioned by the present invention also wrap in addition to including herpes simplex, shingles zoster
Include the skin lesion pain generated during herpes episodes and forerunner's neuralgia and postherpes neuralgia PHN.
The beneficial effects of the present invention are: Chinese medicine composition of the invention uses traditional Chinese medicine for raw material, and toxic side effect is small,
It is obvious to treat shingles zoster effect, and postherpes neuralgia PHN can be prevented and treated.Either systemic administration or part
Medication, effect are better than bleb common medicine acyclovir.Chinese medicine composition of the invention can shorten bleb cure time, allow trouble
Person walks out disease shade as early as possible, beneficial to the physical and mental health of patient.
Specific embodiment
It detailed description of a preferred embodiment of the present invention will be given below.The reality of actual conditions is not specified in preferred embodiment
Proved recipe method, usually according to normal condition, illustrated embodiment are but not to be to preferably be illustrated to the contents of the present invention
The contents of the present invention are only limitted to illustrated embodiment.So those skilled in the art are according to foregoing invention content to embodiment party
Case carries out nonessential modifications and adaptations, still falls within protection scope of the present invention.
Embodiment 1
Rhizoma atractylodis 80g, dried orange peel 80g, Cortex Magnoliae Officinalis (ginger system) 80g, root of Dahurain angelica 120g, Poria cocos 120g, shell of areca nut 120g, dried pinellia
80g, extract of licorice root 10g, patchouli oil 0.8ml, perilla leaf oil 0.4ml.Rhizoma atractylodis, dried orange peel, the root of Dahurain angelica, Cortex Magnoliae Officinalis add 60% ethyl alcohol to mention
It takes, filters, filtrate is spare；Poria cocos, the shell of areca nut add water to cook, decocting liquid filtration, and filtrate is spare；Dried pinellia is soaked in water, and is steeped to saturating
After the heart, separately add 13.5 parts by weight of rhizoma zingiberis, add water to cook, decocting liquid filters, and filtrate is spare；Extract of licorice root is smashed rear boiling and is melted；It closes
And said extracted liquid, filtration, filtrate are distilled to recover ethyl alcohol；Patchouli oil, perilla leaf oil is added, mixes, adds water to 1025ml, adjusts
PH to 5.8-6.2 is saved, stands, filters to obtain clear solution, is sterilized, it is filling to obtain solution.
Embodiment 2
Rhizoma atractylodis 80g, dried orange peel 80g, Cortex Magnoliae Officinalis (ginger system) 80g, root of Dahurain angelica 120g, Poria cocos 120g, shell of areca nut 120g, dried pinellia
80g, extract of licorice root 10g, patchouli oil 0.8ml, perilla leaf oil 0.4ml.Rhizoma atractylodis, dried orange peel, the root of Dahurain angelica, Cortex Magnoliae Officinalis add 60% ethyl alcohol to mention
It takes, filters, filtrate is spare；Poria cocos, the shell of areca nut add water to cook, decocting liquid filtration, and filtrate is spare；Dried pinellia is soaked in water, and is steeped to saturating
After the heart, separately add 13.5 parts by weight of rhizoma zingiberis, add water to cook, decocting liquid filters, and filtrate is spare；Extract of licorice root is smashed rear boiling and is melted；It closes
And said extracted liquid, filtration, filtrate are concentrated into the thick paste of relative density 1.30-1.35；Appropriate Macrogol 6000 0 is taken, is heated
Make to melt, patchouli oil, perilla leaf oil and above-mentioned thick paste is added, mix, dripping pelletization, film coating obtains pill.
Embodiment 3
Rhizoma atractylodis 80g, dried orange peel 80g, Cortex Magnoliae Officinalis (ginger system) 80g, root of Dahurain angelica 120g, Poria cocos 120g, shell of areca nut 120g, dried pinellia
80g, extract of licorice root 10g, patchouli oil 0.8ml, perilla leaf oil 0.4ml.Rhizoma atractylodis, dried orange peel, the root of Dahurain angelica, Cortex Magnoliae Officinalis add 60% ethyl alcohol to mention
It takes, filters, filtrate is spare；Poria cocos, the shell of areca nut add water to cook, decocting liquid filtration, and filtrate is spare；Dried pinellia is soaked in water, and is steeped to saturating
After the heart, separately add 13.5 parts by weight of rhizoma zingiberis, add water to cook, decocting liquid filters, and filtrate is spare；Extract of licorice root is smashed rear boiling and is melted；It closes
And said extracted liquid, filtration, filtrate are concentrated into right amount.Patchouli oil, perilla leaf oil are dissolved with appropriate amount of ethanol.Merge above molten
Liquid, mixing adjust ethanol content with ethyl alcohol and appropriate amount of water, and make full dose at 1025ml, stand, and filtration is filling to obtain tincture.
Embodiment 4
Rhizoma atractylodis 80g, dried orange peel 80g, Cortex Magnoliae Officinalis (ginger system) 80g, root of Dahurain angelica 120g, Poria cocos 120g, shell of areca nut 120g, dried pinellia
80g, extract of licorice root 10g, patchouli oil 0.8ml, perilla leaf oil 0.4ml.Rhizoma atractylodis, dried orange peel, the root of Dahurain angelica, Cortex Magnoliae Officinalis add 60% ethyl alcohol to mention
It takes, filters, filtrate is spare；Poria cocos, the shell of areca nut add water to cook, decocting liquid filtration, and filtrate is spare；Dried pinellia is soaked in water, and is steeped to saturating
After the heart, separately add 13.5 parts by weight of rhizoma zingiberis, add water to cook, decocting liquid filters, and filtrate is spare；Extract of licorice root is smashed rear boiling and is melted；It closes
And said extracted liquid, filtration, filtrate are concentrated into the thick paste of relative density 1.15-1.25；Patchouli oil, perilla leaf oil are gathered with appropriate
Ethylene glycol 400 is added in thick paste after dissolving and mixes.Taking polyethylene glycol 4000 is appropriate, is heated to melting in 55 DEG C of water-baths, then plus
Enter above-mentioned thick paste to stir evenly, be cooled to room temperature.
Clinical case
Case selection: all cases are all from May, 2016 to dermatology of Fuling District institute of traditional Chinese medicine of Chongqing City's in March, 2017 door
Diagnose a disease people, is diagnosed as shingles zoster, (Zhao distinguishes chief editor Jiangsu science tech publishing house to diagnostic criteria referring to " clinical dermatology "
The 3rd edition page 302 of April in 2001), it is followed by cluster papule, papulo-vesicle, blister that initial fash, which is erythema, is in tufted；Fash
Along side Substance P, arrangement becomes band, with apparent neuralgia.
Exclusion criteria: known to trial drug Related Component and acyclovir allergy sufferers；There is serious immunologic hypofunction,
Or cortin and immunosuppressor person need to be taken for a long time；There are the serious heart, Liver and kidney function impairer；With psychoneural disease
Disease or the serious blood circulatory system and endocrine system disease person；Antiviral drugs and immunomodulator were applied in 1 week；Gestation and the food in one's mouth
Newborn phase women；There are excessive drinking history or drug abuse history person in the recent period；Other drugs experimenter was participated in 3 months.
Patient's grouping: finally having 84 patients to complete experiment, wherein male 43, and women 41, average age 47.6 years old,
Patient is equally divided into three groups, and every group of 28 people are successively numbered according to consultation time and sign informed consent form.Three groups it
Between male to female ratio, age distribution, course of disease time without significant difference, is comparable.
Treatment method
Trial drug group 1: embodiment 10mL of 1 solution, twice a day；
Trial drug group 2: 4 ointment of embodiment applies affected part；Six times a day.
Control group 3: acyclovir 2.0g intravenous drip, once a day；Acyclovir ointment applies affected part, six times a day.
Data statistics: it is analyzed using 18.0 statistical analysis software of SPSS.Measurement data with mean ± standard deviation (x ±
SD it) indicates, data compare between group is examined using t, and P < 0.05 indicates that difference is statistically significant.
Symptom and sign evaluation index and result
(1) scores of erythema: 0 point: nothing；1 point: light red；2 points: red, no oedema；3 points: scarlet, Mild edema；4 points: it is dark red,
Obvious oedema.
* P < 0.05 is indicated
(2) blister size scores: 0 point: without blister；1 point: blister is dry or forms a scab；2 points: blister diameter≤0.2cm；3
Point: 0.2cm < blister diameter≤0.4cm；4 points: blister diameter > 0.5cm.
(3) blister form scores: 0 point: without blister or incrustation；1 point: papulo-vesicle；2 points: limpid vesicle fluid is without ulceration；3 points: blister
Liquid is muddy or slight erosion；4 points: blood blister, warts or fester.
Blister size and form score are total, and statistics scoring is as follows in treatment cycle:
* P < 0.05 is indicated
(4) skin lesion pain degree scores: right using visual analogue scales (Visual Analogue Scale, VAS)
The pretherapy and post-treatment conscious pain intensity of patient is evaluated, and indicates patient pain's intensity and pain to psychological, smart to correspond to score value
Impact on mind, 0 point is painless；1~3 point: mild pain can still be engaged in normal activity；4~6 points of moderate pains, influence work
Make, but life remains to take care of oneself；7~10 points, severe pain seriously affects Working Life.
| Group | Before treatment | 1d | 5d | 7d | 10d |
| Medicine group 1 | 2.53±0.27 | 2.12±0.14 | 1.68±0.15* | 1.22±0.14* | 0.82±0.24* |
| Medicine group 2 | 2.51±0.36 | 2.15±0.32 | 1.64±0.27* | 1.20±0.18* | 0.61±0.26* |
| Control group | 2.55±0.24 | 2.36±0.26 | 2.03±0.13 | 1.85±0.26 | 1.81±0.41 |
* P < 0.05 is indicated
(5) a situation arises for post herpetic neuralgia: 30 days follow-up nerve pain situations after bleb clinical healing, counts as follows:
| Group | N | Number of cases occurs for post herpetic neuralgia | Incidence |
| Medicine group 1 | 28 | 0 | 0 |
| Medicine group 2 | 28 | 0 | 0 |
| Control group | 28 | 4 | 14.3% |
Clinical treatment outcome shows that using the band-like bleb definite effect of drug therapy of the present invention, and therapeutic effect is obviously excellent
In control drug acyclovir.By clinical treatment, it has surprisingly been found that, drug of the invention is in treatment other clinical symptoms of bleb
While, additionally it is possible to the generation of effective prevention postherpes neuralgia PHN.
Finally, it is stated that the above examples are only used to illustrate the technical scheme of the present invention and are not limiting, although referring to compared with
Good embodiment describes the invention in detail, those skilled in the art should understand that, it can be to skill of the invention
Art scheme is modified or replaced equivalently, and without departing from the objective and range of technical solution of the present invention, should all be covered at this
In the scope of the claims of invention.
Claims (9)
1. a kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases, which is characterized in that
The Traditional Chinese medicine composition formula is as follows: 80 parts by weight of rhizoma atractylodis, 80 parts by weight of dried orange peel, 80 parts by weight of Cortex Magnoliae Officinalis, 120 parts by weight of the root of Dahurain angelica,
120 parts by weight of Poria cocos, 120 parts by weight of the shell of areca nut, 80 parts by weight of dried pinellia, 10 parts by weight of extract of licorice root, 0.8 volume of patchouli oil
Part and 0.4 parts by volume of perilla leaf oil.
2. application of the Chinese medicine composition as described in claim 1 in the drug of preparation treatment herpesvirus infection associated diseases,
It is characterized in that, the preparation method of the Chinese medicine composition includes the following steps: to prepare above-mentioned Chinese medicine by formula ratio, rhizoma atractylodis,
Dried orange peel, the root of Dahurain angelica, Cortex Magnoliae Officinalis add ethyl alcohol to extract, filtration, and filtrate is spare；Poria cocos, the shell of areca nut add water to cook, decocting liquid filtration, and filtrate is spare；
Dried pinellia is soaked in water, and after bubble to the saturating heart, is added water to cook, decocting liquid filtration, and filtrate is spare；Extract of licorice root is smashed rear boiling and is melted,
Filtration, filtrate are spare；Merge above-mentioned filtrate；Patchouli oil is added, perilla leaf oil mixes.
3. Chinese medicine composition as claimed in claim 1 or 2 answering in the drug of preparation treatment herpesvirus infection associated diseases
With, which is characterized in that the drug of the treatment bleb can be any pharmaceutically acceptable dosage form.
4. Chinese medicine composition as claimed in claim 1 or 2 answering in the drug of preparation treatment herpesvirus infection associated diseases
With, which is characterized in that the drug of the preparation treatment bleb further includes pharmaceutical acceptable carrier and/or auxiliary agent.
5. Chinese medicine composition as claimed in claim 1 or 2 answering in the drug of preparation treatment herpesvirus infection associated diseases
With, which is characterized in that the drug of the preparation treatment bleb further includes other active components.
6. Chinese medicine composition as claimed in claim 1 or 2 answering in the drug of preparation treatment herpesvirus infection associated diseases
With, which is characterized in that the herpesviral includes herpes simplex virus I, II type or varicellazoster virus.
7. Chinese medicine composition as claimed in claim 1 or 2 answering in the drug of preparation treatment herpesvirus infection associated diseases
With, which is characterized in that the disease is herpes simplex or shingles zoster caused by herpesvirus infection.
8. Chinese medicine composition as claimed in claim 1 or 2 answering in the drug of preparation treatment herpesvirus infection associated diseases
With, which is characterized in that the disease is that herpesvirus infection is pain caused.
9. Chinese medicine composition as claimed in claim 1 or 2 answering in the drug of preparation treatment herpesvirus infection associated diseases
With, which is characterized in that the disease is skin lesion pain, forerunner's neuralgia or post herpetic neuralgia caused by herpesvirus infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810630565.6A CN108938864A (en) | 2018-06-19 | 2018-06-19 | A kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810630565.6A CN108938864A (en) | 2018-06-19 | 2018-06-19 | A kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108938864A true CN108938864A (en) | 2018-12-07 |
Family
ID=64490473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810630565.6A Pending CN108938864A (en) | 2018-06-19 | 2018-06-19 | A kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108938864A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453280A (en) * | 2019-01-07 | 2019-03-12 | 重庆太极实业（集团）股份有限公司 | A kind of Chinese medicine composition is for treating the application in mucosa injury associated diseases |
| CN109498728A (en) * | 2019-01-07 | 2019-03-22 | 重庆太极实业（集团）股份有限公司 | A kind of antimycotic Chinese medicine composition and its preparation method and application |
| WO2024255913A1 (en) * | 2024-06-18 | 2024-12-19 | 张振涛 | Plaster pharmaceutical composition for targeted inactivation of herpes virus, and preparation method therefor and use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103272092A (en) * | 2012-12-07 | 2013-09-04 | 海南德泽药物研究有限公司 | Huoxiang Zhengqi externally-applied preparation and its preparation method and application |
-
2018
- 2018-06-19 CN CN201810630565.6A patent/CN108938864A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103272092A (en) * | 2012-12-07 | 2013-09-04 | 海南德泽药物研究有限公司 | Huoxiang Zhengqi externally-applied preparation and its preparation method and application |
Non-Patent Citations (1)
| Title |
|---|
| SCORPIOS5Y2: "孕妇患有单纯性疱疹在哪里就医比较靠谱？", 《HTTPS://WENDA.SO.COM/Q/1377649852061727》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453280A (en) * | 2019-01-07 | 2019-03-12 | 重庆太极实业（集团）股份有限公司 | A kind of Chinese medicine composition is for treating the application in mucosa injury associated diseases |
| CN109498728A (en) * | 2019-01-07 | 2019-03-22 | 重庆太极实业（集团）股份有限公司 | A kind of antimycotic Chinese medicine composition and its preparation method and application |
| WO2024255913A1 (en) * | 2024-06-18 | 2024-12-19 | 张振涛 | Plaster pharmaceutical composition for targeted inactivation of herpes virus, and preparation method therefor and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101716214A (en) | Medical composition containing dandelion extract as well as novel application and preparation method thereof | |
| CN1247241C (en) | Liuwei Dihuang dripping pills and its preparation | |
| CN108938864A (en) | A kind of application of Chinese medicine composition in the drug of preparation treatment herpesvirus infection associated diseases | |
| CN1308012C (en) | Chinese medicine composition for treating cerebral hemorrhage and its prepn | |
| CN102872376B (en) | Traditional Chinese medicine composition for nursing or treating diabetic peripheral neuropathy pain | |
| CN102462825B (en) | A kind of compound Chinese medicine for treating depression | |
| CN101933963B (en) | Nasal in-situ gel for treating headache | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN114949105A (en) | Medicinal toothpaste for preventing and treating oral mucositis caused by radiotherapy and chemotherapy | |
| WO2012131643A1 (en) | Herbal compositions comprising pedilanthus tithymaloides for treatment prevention of gastrointestinal disorder | |
| CN101337016A (en) | Medicine for treating postnasal catarrh and its preparation method | |
| CN109453280A (en) | A kind of Chinese medicine composition is for treating the application in mucosa injury associated diseases | |
| CN1457780A (en) | Total alkaloid composition from plant and its pharmaceutical preparation | |
| CN1299692C (en) | Novel usage of jasminoidin | |
| CN103349737A (en) | Traditional Chinese medicine composite for treating headache and preparation method of traditional Chinese medicine composite | |
| JP2001139487A (en) | Medicinal composition of nasal spray or nasal liquid medicine for pyrogenic common cold and method for producing the same | |
| CN110680900B (en) | Medicine for treating recurrent oral ulcer and preparation method thereof | |
| CN105287618A (en) | Oral pharmaceutical composition for treating neuropathic pain and application of pharmaceutical composition | |
| CN110075197A (en) | A kind of Chinese medicine composition that treating herpangina and its preparation and application | |
| CN115887590A (en) | Mongolian medicine medicated bath composition for treating psoriasis as well as preparation method and application thereof | |
| CN105434536A (en) | Medicine composition treating altitude stress and preparation method and application thereof | |
| CN102151316A (en) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathic pain | |
| CN101461846A (en) | Gel for treating zoster and preparation method thereof | |
| CN1541682A (en) | A kind of traditional Chinese medicine preparation for treating insomnia and preparation method thereof | |
| CN112006987A (en) | Cold compress gel for treating rhinitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181207 |